Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian P Selinger

Showing results (101-110 of 114) with videos related to

Pageof 12
Sort By:
Journal of Crohn'S & Colitis|January 23, 2026
Comparative analysis of inflammatory bowel disease patient and service reported quality of care using 2019 and 2023 UK benchmarking data from more than 26,000 adult patient respondents and 154 IBD servicesA Barney Hawthorne, Paul Christiansen, Ian Arnott, et al.
Frontline Gastroenterology|August 15, 2023
Establishing key performance indicators for inflammatory bowel disease in the UKMohammed Nabil Quraishi, Elizabeth Dobson, Rachel Ainley, et al.
Alimentary Pharmacology & Therapeutics|June 30, 2022
Inflammatory bowel disease patient-reported quality assessment should drive service improvement: a national survey of UK IBD units and patientsA Barney Hawthorne, Jackie Glatter, Jonathan Blackwell, et al.
Inflammatory Bowel Diseases|January 1, 2019
Comorbidities Rather Than Age Are Associated With the Use of Immunomodulators in Elderly-onset Inflammatory Bowel DiseaseViraj C Kariyawasam, Shin Kim, Fadi H Mourad, et al.
Frontline Gastroenterology|March 17, 2022
Risk stratifying gastric ulcers: development and validation of a scoring systemWilliam M Brindle, Rebecca K Grant, Marianne Smith, et al.
Alimentary Pharmacology & Therapeutics|October 10, 2019
Assessment of steroid use as a key performance indicator in inflammatory bowel disease-analysis of data from 2385 UK patientsChristian P Selinger, Gareth C Parkes, Ash Bassi, et al.
Alimentary Pharmacology & Therapeutics|December 22, 2021
A propensity score-matched, real-world comparison of ustekinumab vs vedolizumab as a second-line treatment for Crohn's disease. The Cross Pennine study IIMarco Vincenzo Lenti, Vivien Dolby, Tanya Clark, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 6, 2018
A real-world, long-term experience on effectiveness and safety of vedolizumab in adult patients with inflammatory bowel disease: The Cross Pennine studyMarco Vincenzo Lenti, Scott Levison, Elena Eliadou, et al.
BMJ Open Gastroenterology|April 7, 2026
The 2026 IBD UK Standards of healthcare service design and delivery for adults and children living with Crohn's disease and ulcerative colitisChristopher A Lamb, Catherine Picton, Ian Arnott, et al.
The Lancet. Gastroenterology & Hepatology|January 28, 2021
SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statementJames L Alexander, Gordon W Moran, Daniel R Gaya, et al.
Pageof 12

Showing results (101-110 of 114) with videos related to

Sort By:
Pageof 12
Journal of Crohn'S & Colitis|January 23, 2026
Comparative analysis of inflammatory bowel disease patient and service reported quality of care using 2019 and 2023 UK benchmarking data from more than 26,000 adult patient respondents and 154 IBD servicesA Barney Hawthorne, Paul Christiansen, Ian Arnott, et al.
Frontline Gastroenterology|August 15, 2023
Establishing key performance indicators for inflammatory bowel disease in the UKMohammed Nabil Quraishi, Elizabeth Dobson, Rachel Ainley, et al.
Alimentary Pharmacology & Therapeutics|June 30, 2022
Inflammatory bowel disease patient-reported quality assessment should drive service improvement: a national survey of UK IBD units and patientsA Barney Hawthorne, Jackie Glatter, Jonathan Blackwell, et al.
Inflammatory Bowel Diseases|January 1, 2019
Comorbidities Rather Than Age Are Associated With the Use of Immunomodulators in Elderly-onset Inflammatory Bowel DiseaseViraj C Kariyawasam, Shin Kim, Fadi H Mourad, et al.
Frontline Gastroenterology|March 17, 2022
Risk stratifying gastric ulcers: development and validation of a scoring systemWilliam M Brindle, Rebecca K Grant, Marianne Smith, et al.
Alimentary Pharmacology & Therapeutics|October 10, 2019
Assessment of steroid use as a key performance indicator in inflammatory bowel disease-analysis of data from 2385 UK patientsChristian P Selinger, Gareth C Parkes, Ash Bassi, et al.
Alimentary Pharmacology & Therapeutics|December 22, 2021
A propensity score-matched, real-world comparison of ustekinumab vs vedolizumab as a second-line treatment for Crohn's disease. The Cross Pennine study IIMarco Vincenzo Lenti, Vivien Dolby, Tanya Clark, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 6, 2018
A real-world, long-term experience on effectiveness and safety of vedolizumab in adult patients with inflammatory bowel disease: The Cross Pennine studyMarco Vincenzo Lenti, Scott Levison, Elena Eliadou, et al.
BMJ Open Gastroenterology|April 7, 2026
The 2026 IBD UK Standards of healthcare service design and delivery for adults and children living with Crohn's disease and ulcerative colitisChristopher A Lamb, Catherine Picton, Ian Arnott, et al.
The Lancet. Gastroenterology & Hepatology|January 28, 2021
SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statementJames L Alexander, Gordon W Moran, Daniel R Gaya, et al.
Pageof 12